according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Orbifloxacin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Veterinary product

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

1-908-423-6000

#### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 Specific target organ toxicity - repeated exposure, Category 2, Eye H361d: Suspected of damaging the unborn child. H373: May cause damage to organs through prolonged or repeated exposure if swallowed.

#### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Eye) through pro-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

longed or repeated exposure if swallowed.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

### Hazardous components which must be listed on the label:

Orbifloxacin

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Orbifloxacin	113617-63-3	Repr. 2; H361d	>= 3 - < 10
Lactic acid	50-21-5 200-018-0	Skin Corr. 1C; H314 Eye Dam. 1; H318 EUH071	>= 1 - < 3
Sodium hydroxide	1310-73-2 215-185-5 011-002-00-6	Met. Corr. 1; H290 Skin Corr. 1A; H314 Eye Dam. 1; H318 EUH014, EUH071	>= 1 - < 2

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

Version 4.4	Revision Date: 28.09.2024	SDS Number: 785871-00021	Date of last issue: 06.04.2024 Date of first issue: 28.06.2016	
			specific concentration limit Skin Corr. 1A; H314 >= 5 % Skin Corr. 1B; H314 2 - < 5 % Skin Irrit. 2; H315 0.5 - < 2 % Eye Irrit. 2; H319 0.5 - < 2 % EUH071	

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

>= 2 %

advice.

Protection of first-aiders First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment

when the potential for exposure exists (see section 8).

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

### **SECTION 5: Firefighting measures**

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides
Metal oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

Gases

#### 7.3 Specific end use(s)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

Specific use(s) : No data available

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m3	IE OEL
		OELV - 8 hrs (TWA) (total (va- pour and parti- cles))	150 ppm 470 mg/m3	IE OEL
Orbifloxacin	113617-63- 3	TWA	0.2 mg/m3 (OEB 2)	Internal
Silicon dioxide	7631-86-9	OELV - 8 hrs (TWA) (Respira- ble dust)	2.4 mg/m3 (Silica)	IE OEL
		OELV - 8 hrs (TWA) (inhalable dust)	6 mg/m3 (Silica)	IE OEL
Sodium hydroxide	1310-73-2	OELV - 15 min (STEL)	2 mg/m3	IE OEL

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
Silicon dioxide	Workers	Inhalation	Long-term systemic effects	4 mg/m3
Sodium hydroxide	Consumers	Inhalation	Long-term local ef- fects	1 mg/m3
	Workers	Inhalation	Long-term local ef- fects	1 mg/m3

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l
	Freshwater - intermittent	183 mg/l
	Marine water	26 mg/l
	Sewage treatment plant	20000 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

Fresh water sediment	572 mg/kg dry weight (d.w.)
Marine sediment	57.2 mg/kg dry weight (d.w.)
Soil	50 mg/kg dry weight (d.w.)

#### 8.2 Exposure controls

#### **Engineering measures**

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Laboratory operations do not require special containment.

### Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Skin and body protection : Work uniform or laboratory coat.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Physical state : suspension

Colour : light brown

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

**Acute toxicity** 

Not classified based on available information.

### **Components:**

### Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg

Remarks: No mortality observed at this dose.

LD50 (Dog): > 600 mg/kg Symptoms: Vomiting

Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of:

administration)

LD50 (Rat): > 200 mg/kg

Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg Application Route: Intramuscular

LD50 (Rat): 233 mg/kg

Application Route: Intravenous

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

LD50 (Mouse): 250 mg/kg Application Route: Intravenous

Lactic acid:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: Based on data from similar materials

Acute inhalation toxicity : LC50 (Rat): > 5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract. Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Assessment: The substance or mixture has no acute dermal

oxicity

Remarks: Based on data from similar materials

Sodium hydroxide:

Acute inhalation toxicity : Assessment: Corrosive to the respiratory tract.

#### Skin corrosion/irritation

Not classified based on available information.

**Product:** 

Species : Rabbit

Result : No skin irritation

Components:

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Lactic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : Corrosive after 1 to 4 hours of exposure Remarks : Based on data from similar materials

Sodium hydroxide:

Result : Corrosive after 3 minutes or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

**Product:** 

Species : Rabbit

Result : Mild eye irritation

**Components:** 

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : Mild eye irritation

Lactic acid:

Species : Chicken eye

Remarks : Based on data from similar materials

Result : Irreversible effects on the eye

Sodium hydroxide:

Result : Irreversible effects on the eye Remarks : Based on skin corrosivity.

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Product:** 

Test Type : Magnusson-Kligman-Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

**Components:** 

Orbifloxacin:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Lactic acid:

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

Sodium hydroxide:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact Result : negative

Germ cell mutagenicity

Not classified based on available information.

**Components:** 

Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: equivocal

Test Type: Mouse Lymphoma

Result: positive

Test Type: Chromosomal aberration Test system: Human lymphocytes

Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow

Application Route: Intraperitoneal injection

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Application Route: Oral

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Lactic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

Result: negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

#### Components:

#### Orbifloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years

NOAEL : 200 mg/kg body weight

Result : negative

#### Lactic acid:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

Remarks : Based on data from similar materials

### Reproductive toxicity

Suspected of damaging the unborn child.

#### **Components:**

#### Orbifloxacin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: NOAEL: 50 mg/kg body weight Early Embryonic Development: NOAEL: 50 mg/kg body

weight

Result: No adverse effects

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high ma-

ternally toxic doses

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

General Toxicity Maternal: NOAEL: 20 mg/kg body weight Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal

body weight gain

Test Type: Development

Species: Dog

**Application Route: Oral** 

Developmental Toxicity: LOAEL: 2.5 mg/kg body weight Result: Effects on postnatal development, Skeletal malfor-

mations

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

Lactic acid:

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Ingestion

Result: negative

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs (Eye) through prolonged or repeated exposure if swallowed.

**Product:** 

Target Organs : Eye

Assessment : May cause damage to organs through prolonged or repeated

exposure.

### Repeated dose toxicity

**Product:** 

Species : Dog
NOAEL : 22.5 mg/kg
LOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 30 Days

Symptoms : Gastrointestinal disturbance

Species : Dog LOAEL : 75 mg/kg Application Route : Oral Exposure time : 10 Days

Symptoms : Salivation, Gastrointestinal disturbance, Vomiting

Species : Cat

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

LOAEL : 45 mg/kg
Application Route : Oral
Exposure time : 30 Days
Target Organs : Eye

Symptoms : Salivation, Lachrymation, Gastrointestinal disturbance, Liver

disorders

#### **Components:**

Orbifloxacin:

Species : Rat
NOAEL : 20 mg/kg
LOAEL : 80 mg/kg
Application Route : Oral
Exposure time : 3 Months

Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse
NOAEL : 80 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 3 Months

Species : Juvenile dog
NOAEL : 50 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 14 Days
Target Organs : Heart, Bone

Symptoms : Gastrointestinal disturbance

Remarks : mortality observed

Species : Juvenile dog
NOAEL : 2 mg/kg
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Bone

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 37.5 mg/kg Application Route : Oral Exposure time : 30 Days

Species : Cat

NOAEL : 7.5 mg/kg

LOAEL : 22.5 mg/kg

Application Route : Oral

Exposure time : 1 Months

Symptoms : Gastrointestinal disturbance

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

Lactic acid:

Species : Rat

NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 13 Weeks

Remarks : Based on data from similar materials

Species : Rat

LOAEL : 886 mg/kg
Application Route : Skin contact
Exposure time : 13 Weeks

**Aspiration toxicity** 

Not classified based on available information.

#### 11.2 Information on other hazards

### **Endocrine disrupting properties**

**Product:** 

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### **Components:**

Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal

disturbance, liver function change, anaphylaxis, Rash

Remarks: May cause photosensitisation.

### **SECTION 12: Ecological information**

### 12.1 Toxicity

#### **Components:**

Lactic acid:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: Based on data from similar materials

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.4 28.09.2024 785871-00021 Date of first issue: 28.06.2016

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

NOEC (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50 : > 10 - 100 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Remarks: Based on data from similar materials

### 12.2 Persistence and degradability

#### **Components:**

Lactic acid:

Biodegradability : Result: Not readily biodegradable.

Remarks: Based on data from similar materials

#### 12.3 Bioaccumulative potential

### **Components:**

Lactic acid:

Partition coefficient: n-

octanol/water

: log Pow: -0.62

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

#### 12.7 Other adverse effects

No data available

#### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.4 Packing group

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

IMDG : Not regulated as a dangerous good
 IATA (Cargo) : Not regulated as a dangerous good
 IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

not.

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

: Not applicable

Regulation (EC) on substances that deplete the ozone

layer

: Not applicable

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

: Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

: Not applicable

: Not applicable

REACH - List of substances subject to authorisation

(Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

#### Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.04.2024

 4.4
 28.09.2024
 785871-00021
 Date of first issue: 28.06.2016

regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

#### **Full text of H-Statements**

H290 : May be corrosive to metals.

H314 : Causes severe skin burns and eye damage.

H318 : Causes serious eye damage.

H361d : Suspected of damaging the unborn child.

EUH014 : Reacts violently with water. EUH071 : Corrosive to the respiratory tract.

### Full text of other abbreviations

Eye Dam. : Serious eye damage Met. Corr. : Corrosive to metals Repr. : Reproductive toxicity Skin Corr. : Skin corrosion

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)
IE OEL / OELV - 15 min : Occupational exposure limit value (15-minute reference period)

(STEL) od

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China;

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## **Orbifloxacin Liquid Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 4.4 28.09.2024 785871-00021 Date of first issue: 28.06.2016

IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

Classification of the mixture:

Classification procedure:

Repr. 2 H361d Calculation method

STOT RE 2 H373 Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN